The present study aims to evaluate the impact of COVID-19 disease and its treatment on ventricular repolarization, assessed by measuring the QTc interval, in patients admitted to the critical care unit.
Coronavirus infection of Severe Acute Respiratory Syndrome COVID-2 is characterized by a
broad clinical spectrum ranging from asymptomatic infection, mild upper respiratory tract
disease and severe viral pneumonia with respiratory failure and even death, with many
patients hospitalized with pneumonia. In addition, the infection can have a direct impact on
cardiovascular disease including the development of arrhythmias, although the exact incidence
is not known. Treatments administered for COVID-19 infection have the potential to produce
adverse cardiovascular effects including prolongation of the QT interval and development of
arrhythmias.
Relevant clinical data that may affect the QT interval and specifically the medication the
patient has received will be recorded. The specific treatment administered for COVID-19 will
be recorded as the concomitant medication of the critical patient that may have an impact on
the QT interval. Analytical data will also be collected on plasma levels of ions such as
potassium, calcium and magnesium, blood gases, renal and hepatic function parameters and
cardiac markers.
Inclusion Criteria:
- Patients admitted to intensive care units for COVID-19 infection with an ECG record
Exclusion Criteria:
- Patients in critical care unit without COVID-19 infection
Servicio de Anestesia, Hospital General Universitario Gregorio Marañon
Madrid, Spain
Investigator: Matilde Zaballos, MD, PhD
Contact: 0034915868367
mati@plagaro.net
Matilde Zaballos, MDPhD
0034657813987
mati@plagaro.net
Javier Hortal, MD PhD
915868367
javier.hortal@gmail.com
Javier Hortal, MD PhD, Study Chair
Hospital Universitario Gregorio Marañon